Rodan + Fields Prostaglandin Lash Boost Suit Appears Headed For Settlement
The San Francisco-based multi-level beauty marketer seems intent on putting an end to a multi-year, consolidated putative class action in California federal court alleging it failed to disclose risks associated with the prostaglandin analog in its Lash Boost conditioning serum.
You may also be interested in...
The Scientific Committee on Consumer Safety will consider available safety data for prostaglandin analogs isopropyl cloprostenate, ethyl tafluprostamide and others with known use in eyelash-growth cosmetic products in the EU. Currently, the substances are not restricted in cosmetic products.
Marketers of cosmetic lash enhancers that haven’t abandoned prostaglandin analogs in favor of peptides or botanical extracts should take heed of a proposed class action against Rodan + Fields in California’s Northern District. Plaintiffs say they would not have purchased the firm’s Lash Boost and suffered alleged adverse effects if they’d been properly informed about product risks.
Latisse marketer Allergan continues to lock horns with cosmetic firms offering non-FDA-approved, prostaglandin-based eyelash-enhancement products, pursuing injunction and damages in California court.